AstraZeneca Stock (NASDAQ:AZN)
Previous Close
$66.29
52W Range
$61.24 - $87.68
50D Avg
$73.38
200D Avg
$74.13
Market Cap
$421.71B
Avg Vol (3M)
$6.16M
Beta
0.25
Div Yield
$1.54 (1.42%)
AZN Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Soliris | $3.15B | $3.76B | - |
| Strensiq | $1.15B | $958.00M | - |
| Symbicort | $2.36B | $2.54B | - |
| Synagis | $546.00M | $578.00M | - |
| Tagrisso | $5.80B | $5.44B | - |
| Total Oncology | $17.14B | $14.63B | - |
| Total Other medicines | $1.18B | $1.63B | - |
| Ultomiris. | $2.96B | $1.97B | - |
| Vaxzevria | $12.00M | $1.80B | - |
| Zoladex | $952.00M | $927.00M | $948.00M |
| Andexxa | $182.00M | $150.00M | - |
| Bydureon | $163.00M | $280.00M | - |
| Daliresp/Daxas | $54.00M | $189.00M | - |
| Farxiga | $5.96B | $4.38B | - |
| Fasenra | $1.55B | $1.40B | - |
| Faslodex | $297.00M | $334.00M | - |
| Imfinzi | $4.24B | $2.78B | - |
| Koselugo | $331.00M | $208.00M | - |
| Lokelma | $412.00M | $289.00M | - |
| Pulmicort | $713.00M | $645.00M | - |
| Onglyza | $227.00M | $257.00M | - |
| Oncology, Others | $224.00M | $44.00M | - |
| Nexium | $945.00M | $1.28B | $1.33B |
| Kanuma | $171.00M | $160.00M | - |
| Calquence | $2.51B | $2.06B | - |
| Crestor | $1.11B | $1.05B | $1.10B |
| Enhertu | $1.02B | $79.00M | $17.00M |
| FluMist | $216.00M | $175.00M | - |
| Breztri | $677.00M | $398.00M | - |
| Brilinta | $1.32B | $1.36B | - |
| CVRM | $10.59B | $9.19B | - |
| Lynparza | $2.81B | $2.64B | - |
| Roxadustat | $271.00M | $197.00M | $174.00M |
| Rare Disease | $7.76B | $7.05B | - |
| Bevespi | $58.00M | $58.00M | - |
| Other, Others | $231.00M | $340.00M | - |
| Saphnelo | $280.00M | $116.00M | - |
| Seloken/Toprol-XL | $640.00M | $862.00M | - |
| Arimidex | - | $99.00M | - |
| BioPharmaceuticals: total Respiratory & Immunology | - | $5.76B | - |
| Respiratory, Others | - | $421.00M | - |
| Ophatys | - | $33.00M | - |
| Iressa | - | $114.00M | - |
| Casodex | - | $78.00M | - |
| Collaboration Revenue | - | - | $12.00M |
| Lynparza/Koselugo | - | - | $400.00M |
| Royal income | - | - | $138.00M |
| Other Ongoing Collaboration Revenue | - | - | $64.00M |
| Profit share revenue from product sales by collaboration partners | - | - | $200.00M |
Fiscal year ends in Dec 23 | Currency in USD